Can Stem Cell Therapy Help Lower Back Pain?

Possibly, for some people, but the answer is not settled. Small randomized trials of stem cell injections into painful, degenerated discs have reported modest improvements in pain and function, while the most recent sham-controlled trial found no clear advantage over a sham procedure at six months (Vadalà, Russo, Ambrosio, et al., 2025; Xie et al., 2021). No stem cell product is FDA-approved for back pain or disc disease (U.S. Food and Drug Administration [FDA], 2024).

What This Means

Most research on stem cells for low back pain focuses on one pain source: the intervertebral disc, the cushion between two vertebrae. With age, injury and genetics, discs lose water and height. When a degenerated disc is the pain generator, the pain often worsens with sitting and bending. This is called discogenic low back pain.

The cells studied are mostly mesenchymal stromal cells (MSCs), taken from a patient's own bone marrow or fat, or from a donor source such as umbilical cord tissue. In the trials, they were injected directly into the disc under image guidance. The idea is that the cells may calm inflammation and support the disc's own cells. Whether that translates into lasting pain relief in people is exactly what the trials are trying to answer (Vadalà, Russo, Papalia, et al., 2025).

"Stem cell therapy for back pain" advertised by a clinic may mean something quite different from what was tested: a different product, a different dose, or an injection somewhere other than the disc. Results from disc trials do not automatically apply to those uses.

Candidacy

The people enrolled in these studies were narrowly chosen. A 2025 systematic review found participants averaged about 41 years old, had chronic low back pain traced to one or more degenerated discs, and had not improved with conservative care such as exercise and medication (Vadalà, Russo, Papalia, et al., 2025).

That profile excludes many people with back pain. Pain from the facet joints, the sacroiliac joint, a pinched nerve, spinal stenosis or muscle strain is a different problem. So is back pain with warning signs such as new leg weakness, loss of bladder or bowel control, fever or unexplained weight loss, which needs prompt medical attention rather than an elective procedure. Candidacy for any cell-based option is a physician's decision after a full evaluation.

Clinical Evaluation

An evaluation at PrimeCell Regenerative starts with your history, a musculoskeletal and neurological exam, and a review of prior imaging. Disc degeneration appears on MRI in many adults who have no pain at all, so an imaging finding alone does not prove the disc is the source.

I look at where the pain sits, what positions make it worse, whether it travels into the leg, and what has already been tried. Some next steps, such as epidural steroid injections, radiofrequency ablation or nerve studies, are not performed at PrimeCell; when one of them fits, I coordinate with or refer you to a spine specialist.

Available Options

Mainstream care comes first. The American College of Physicians recommends that people with chronic low back pain start with non-drug approaches such as exercise, multidisciplinary rehabilitation, acupuncture, mindfulness-based stress reduction, tai chi, yoga, cognitive behavioral therapy or spinal manipulation. If those are not enough, the guideline lists nonsteroidal anti-inflammatory drugs first, with tramadol or duloxetine as second-line choices (Qaseem et al., 2017).

Beyond that, interventional spine procedures and, for selected cases, surgical consultation may be discussed. At PrimeCell, platelet-rich plasma (PRP) or, less often, a cell-based product may be discussed for selected patients with a clearly identified source, such as the sacroiliac joint or spinal ligaments. Those sites differ from the disc trials described below, and that difference is part of the consent conversation. For how PRP and cell-based products compare, see PRP vs. stem cell therapy.

Benefits, Limitations and Risks

The possible benefit is a modest, gradual reduction in pain and disability for carefully selected people with disc-related pain. In the published trials, serious complications were uncommon, and a 2021 meta-analysis found no significant difference in adverse events between cell and control groups (Xie et al., 2021).

The limitations are substantial. Trials used different cell sources, doses and injection methods, so there is no agreed-upon protocol (Vadalà, Russo, Papalia, et al., 2025). Any needle into a disc carries risks, including infection of the disc space and flare-ups of pain. FDA has received reports of serious harm from unapproved regenerative products, including infections, tumor formation, unwanted immune reactions and contamination during processing (FDA, 2024). Insurance generally does not pay for these procedures, and results vary from person to person.

What the Evidence Shows

What it does establish. A 2021 meta-analysis of randomized trials found that MSC injections lowered pain scores at 3, 6, 12 and 24 or more months and lowered disability scores at 24 or more months compared with control groups (Xie et al., 2021). A 2025 systematic review of 10 published studies (736 participants) reported modest improvements in pain, disability and quality of life, with occasional MRI signs of increased disc hydration (Vadalà, Russo, Papalia, et al., 2025).

What it does not establish. In the DREAM trial, 52 people with multilevel disc degeneration were randomized to their own bone-marrow cells or a sham procedure. The injections appeared safe, but there was no significant clinical advantage over sham at six months; this was a preliminary report, and longer follow-up is pending (Vadalà, Russo, Ambrosio, et al., 2025). The same research group concluded that small sample sizes, few randomized trials and moderate risk of bias do not allow firm conclusions about effectiveness (Vadalà, Russo, Papalia, et al., 2025). No study has shown that stem cells reliably rebuild a degenerated disc, and FDA lists back pain and disc disease among conditions for which regenerative therapies are not approved (FDA, 2024).

Recovery and Next Steps

In research settings, people typically return to light activity within days, with soreness at the injection site common at first. Trials judged results over months, not weeks. A return to guided exercise remains part of the plan either way.

If you are considering a cell-based procedure for back pain, bring prior imaging reports and a list of therapies, medications and injections you have tried. Ask exactly where the injection will go and why, what product will be used and where it comes from, what its FDA status is, and how progress will be measured.

Orlando Considerations

Florida law requires physicians who perform stem cell therapies not approved by FDA to give patients the notice shown on this page. PrimeCell is a self-pay practice. Any regenerative spine procedure is quoted in a written estimate after the evaluation, and qualifying patients can use Cherry payment plans. For more on how costs are set, see Cost & written estimates.